Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 12 MAY 2026

PCOS Name Changes To PMOS: Will PCOS’ Name Change Impact Patent Applications

Potter Clarkson LLP
Explore more from Potter Clarkson LLP

Polycystic Ovary Syndrome has been officially renamed Polyendocrine Metabolic Ovarian Syndrome following a 14-year global medical consensus. The new terminology better reflects the condition's complex hormonal, metabolic and reproductive nature, moving beyond the misleading reference to ovarian cysts. What does this fundamental shift in medical understanding mean for patent applications and intellectual property strategy in women's health innovation?

DenmarkIntellectual Property
Alice Mortiboy
Alice Mortiboy
Author LinkedIn connections

Polycystic Ovary Syndrome (PCOS) has officially been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) after a global medical consensus. Experts say the new name better reflects the condition's hormonal, metabolic and reproductive impact on millions of women, but will PCOS’ name change impact patent applications?

Polycystic ovary syndrome (PCOS) has long been recognised as a common condition affecting approximately one in eight women worldwide, but the terminology has increasingly been viewed as scientifically inaccurate and clinically misleading.

The term 'polycystic' implies the presence of pathological ovarian cysts, despite evidence that many patients do not have such cysts, and that the condition is in fact a complex, multisystem disorder involving endocrine, metabolic, reproductive, and psychological features. This mismatch has been associated with delayed diagnosis, fragmented care, and constrained research and policy framing. [ref: the lancet]

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

View source

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

AI Training Meets Copyright Law: Munich Court Sides With GEMA Against OpenAI

On 11 November 2025, the Regional Court of Munich I ruled that OpenAI’s language models unlawfully used song lyrics by nine German authors. GEMA, acting as the collecting society, claimed that OpenAI’s models had memorised and reproduced copyrighted lyrics without permission. Comparable collecting societies across Scandinavia – such as KODA (Denmark) play similar roles in protecting authors’ rights and are closely watching this development.
DenmarkIntellectual Property
Aera A/S
Aera A/S
Article

EPO Enlarged Board Clarifies: Publicly Available Products Are Prior Art, Even If Irreproducible

The European Patent Office's Enlarged Board has fundamentally altered the landscape of prior art assessment, establishing that products made publicly available before a patent filing date constitute prior art regardless of whether they can be analyzed or reproduced. This landmark decision removes the long-standing reproducibility requirement, making market availability alone sufficient to destroy novelty and significantly raising the stakes for timely patent filings.
European UnionIntellectual Property
Aera A/S
Aera A/S
Article

AI And Copyright: What Are The Implications Of The Getty And Gema Cases For The Danish Corporate Sector?

Two recent European court cases—Getty Images vs Stability AI and Gema vs OpenAI—have delivered contrasting rulings on generative AI and copyright infringement, with significant implications for how businesses assess legal risks when using AI models. While one court found no infringement in AI training processes, the other ruled that memorized copyrighted content in model outputs constitutes unlawful reproduction, highlighting the urgent need for Danish companies to clarify their AI roles and imp
DenmarkIntellectual Property
Bech-Bruun
Bech-Bruun
Article

AI og ophavsret: Hvad betyder Getty- og Gema-sagerne for danske virksomheder?

To nye europæiske domme om generativ AI og ophavsret viser, at både træningsdata og AI-genereret output kan få afgørende betydning i kommende sager. Getty Images mod Stability AI og Gema mod OpenAI illustrerer, hvordan retsstillingen fortsat er uafklaret på tværs af jurisdiktioner. Hvad betyder disse afgørelser for danske virksomheder, der anvender eller udvikler AI-løsninger?
DenmarkIntellectual Property
Bech-Bruun
Bech-Bruun
Article

EHDS And The Future Of Health Data Transactions In Europe

The European Health Data Space (EHDS) regulation has entered into force, creating a harmonised framework for cross-border health data access across the EU. While Europe possesses exceptional health data resources—particularly in Nordic countries with comprehensive patient registries—it has historically lacked the commercial data market infrastructure seen in the United States. This analysis explores how life science companies and investors can position themselves to capitalise on emerging opport
European UnionFood, Drugs, Healthcare, Life Sciences
Potter Clarkson LLP
Potter Clarkson LLP
Article

G 1/25: Description Amendments At The EPO - Business As Usual?

The Enlarged Board of Appeal has issued its decision in G 1/25, addressing a fundamental question in European patent practice: when must patent descriptions be amended to align with amended claims? This landmark ruling establishes new guidance on the relationship between claims and descriptions, building upon the interpretive framework set forth in G 1/24 and potentially reshaping how practitioners approach description amendments at the EPO.
AfghanistanIntellectual Property
Potter Clarkson LLP
Potter Clarkson LLP